|Marketing Regulation of Drugs in India|
|Life Sciences - Life Science Article|
Role of Regulatory Authorities in Marketing Regulation of Drugs in India
Approval of the drug product for import, manufacturing and marketing in India, its demonstration for safety and efficacy in humans is essential. The Rules 122A, 122B and 122D, 122 DA, 122DAA, 122E and Appendix I, IA and VI of Schedule Y of the Drugs & Cosmetics Act, 1945, describes the information/data required for approval of clinical trial and/or to import, manufacture, or market any new drug in the country. However, the requirements for approval of clinical trials and new drugs may vary depending on the nature of new drugs.
The whole 11 pages article is available for download at Downloads section of Farmavita.Net.
Government oversight of the pharmaceutical industry is usually classified into preapproval and post-approval categories. Most of the therapeutically significant compounds marketed today are the subject of new drug applications (NDAs) and abbreviated new drug applications (ANDAs). Preapproval activities, based on these detailed applications, are used to assure the drug is safe and effective before marketing.
After the drug is approved and marketed, periodic unannounced inspections of drug production and control facilities by FDA’s field investigators and analysts are conducted. The FDA uses different mechanisms for assuring that firms adhere to the terms and conditions of approval described in the application and that the drug is manufactured in a consistent and controlled manner. The Federal Food drug and Cosmetic Act (FD&C Act) provides legal authority for inspection. These regulations, Current Good Manufacturing Practice for Finished Pharmaceuticals, are contained in Part 211 of Title 21 of the U.S. Code of Federal Regulations. This regulation contains requirements for Organization and Personnel; Buildings and Facilities; Equipment; Components, Containers, and Closures; Production and Process Control; Packaging and Labeling; Distribution; Laboratory; and Reports and Records.
The regulations are general enough to be applied to a wide variety of dosage form drugs from topical ointments and creams to sterile injectables and ophthalmics. FDA investigators often use additional information from a variety of market surveillance systems to assist them in identifying a manufacturing or control problem. These laboratories confirm suspected chemical, physical, and microbiological problems with pharmaceuticals; verify and develop analytical methods; and conduct research. This system of regulation has grown with the pharmaceutical industry through many crises and challenges. The FDA welcomes dialogue with other regulatory bodies, industry organizations, Congress, and the public to improve the efficiency of its regulatory and administrative processes.
The whole 11 pages article is available for download at Downloads section of Farmavita.Net.Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Membership at Farmavita.Net is Free
Register yourself and connect with community of 600+ pharmaceutical executives, researchers and innovators. Expand your professional network and find new business and career development opportunities.
Click here for registration!